MHC class II-restricted T cell receptor (MHC-II restricted TCR)

The T cell receptor (TCR) recognizing tumor peptide–MHC class II complexes is a specialized receptor complex primarily found on CD4+ T cells that plays a pivotal role in the adaptive immune response against cancer. Unlike the more commonly studied MHC class I-restricted TCRs, these receptors recognize antigenic peptides derived from tumor proteins that are processed and presented by Major Histocompatibility Complex (MHC) class II molecules. Upon recognition of a specific tumor-associated antigen or neoantigen, the TCR triggers a signaling cascade through the CD3 complex, leading to T cell activation, proliferation, and the secretion of effector cytokines such as interferon-gamma and tumor necrosis factor. These activated CD4+ T cells can provide essential help to CD8+ cytotoxic T cells or directly eliminate MHC class II-positive tumor cells through perforin and granzyme-mediated pathways. In the field of oncology, this receptor complex is the primary focus of MHC class II-restricted TCR-engineered T cell (TCR-T) therapies, which aim to redirect a patient's immune system to specifically attack tumors expressing the cognate antigen. Such therapies are particularly valuable for targeting tumors that have downregulated MHC class I or for antigens that are preferentially presented in the MHC class II pathway. Clinical development of these therapies focuses on antigens like MAGE-A3, NY-ESO-1, and various somatic neoantigens, often restricted by specific HLA alleles such as HLA-DPB1*0401. However, therapeutic application faces significant challenges, including potential on-target off-tumor toxicities and the risk of severe immune-related adverse events like cytokine release syndrome.

Other names

T cell receptor recognizing tumor peptide–MHC class II complexCD4+ T cell receptorHLA class II-restricted T cell receptorpMHC-II-specific TCRTumor-specific MHC class II-restricted TCR

Adoptive T cell therapy (TCR-T) where T cells are genetically engineered to express a specific TCR that recognizes tumor-derived peptides presented by MHC class II molecules, triggering direct tumor cell lysis and the release of pro-inflammatory cytokines to orchestrate an anti-tumor immune response.